Recombinant Human Serine/threonine-protein kinase PLK2 (PLK2)

1. The p53 dependence of Plk2 loss and tumor suppressor function in relationship to mTOR signaling may have therapeutic implications. PMID: 29448085
2. FOXD1 promoted the expression of Plk2 mRNA and protein in colorectal cancer cells. PMID: 29864920
3. we discovered that PLK2 might be inactivated in microsatellite-instability high colorectal cancers, suggesting that PLK2 could be a tumor-suppressing gene in these cancers. PMID: 28698103
4. study demonstrates that PLK-2 activity can rapidly change cellular alpha-synuclein levels in cell models and in mice brains, but this process does not require phosphorylation of S129. Instead, it operates via regulation of alpha-synuclein mRNA transcription in an open reading frame-dependent manner PMID: 28648742
5. Findings indicate the interaction network of viral oncogene HPV16 E7, miR-27b and PLK2, and support the potential strategies using antisense nucleic acid of miR-27b for therapy of cervical cancer. PMID: 26910911
6. CHOP negatively regulates Polo-like kinase 2 expression via recruiting C/EBPalpha to the upstream-promoter in human osteosarcoma cell line during ER stress PMID: 28652211
7. Plk2 represents an independent prognostic marker and regulates tumor growth and apoptosis by targeting Fbxw7/Cyclin E pathway in colorectal carcinoma. PMID: 27423313
8. PLK2 kinase has a role in mediating alpha-synuclein selective autophagic degradation PMID: 28154193
9. PLK2, functional kinase and polo-box domains were required for interaction with PFV Gag. Fluorescently-tagged PFV Gag, through its chromatin tethering function, selectively relocalized ectopically expressed eGFP-tagged PLK proteins to mitotic chromosomes i PMID: 27579920
10. Develop a DDS for continuous intracellular delivery of PLK2. PMID: 27863657
11. Structural analysis of the polo-box domain of human PLK2 has been presented. PMID: 25846005
12. our study demonstrates a novel mechanism of PLK2 in promoting tumor progression, whereby it directly binds to enriched TAp73, catalyzes Ser48 phosphorylation of TAp73, and inhibits TAp73 transcriptional activity PMID: 26625870
13. Data suggest wild-type SNCA (alpha-synuclein) binding to synaptosome membrane is not affected by phosphorylation by PLK2; A30P SNCA, a Parkinson disease mutation, binding is greatly increased; endocytosis of SNCA fibrils follows similar pattern. PMID: 26719332
14. Decreased PLK2 protein expression due to promoter hypermethylation was negatively correlated with JAK2 overexpression, a common occurrence in hematological malignancies. PMID: 25347426
15. PLK2 SNPs were associated with Alzheimer disease and mild cognitive impairment. PLK2-rs15009 CC and GG genotypes and CC genotype at PLK2-rs702723 were protective for AD. PMID: 24384746
16. PLK2 indirectly activates ROCK2 via phosphorylating nucleophosmin during centrosome amplification. PMID: 25590559
17. these findings reveal a conserved PLK2-RAP1 pathway that is crucial to regulate endothelial tip cell behavior in order to ensure proper vascular development and patterning in vertebrates. PMID: 26004360
18. Silencing of polo-like kinase 2 increases cell proliferation and decreases apoptosis in SGC-7901 gastric cancer cells. PMID: 25501818
19. Unique PLK2-dependent protein phosphorylation sites identified by mass spectrometry. PMID: 25338102
20. the regulation of redox homeostasis by PLK2 promotes the survival of cells with dysfunctional mitochondria PMID: 24887096
21. Data shows that PLK2 mRNA is a direct target of miR-27a in laryngeal squamous cell carcinoma. PMID: 25239093
22. this study reports the first crystal structure of the C-terminal polo-box domain of PLK2. PMID: 25511705
23. Study indicates that miR-126 is a tumor suppressor that inhibits gastric cancer cells proliferation by targeting PI3KR2, Crk and PLK2. PMID: 24969300
24. This study supports a role for PLK2 in the generation of aSyn inclusions by a mechanism that does not depend directly on serine 129 phosphorylation. PMID: 23677647
25. Our findings suggest a new role for PLK2 in the regulation of inflammatory diseases by modulating ADAM17 activity. PMID: 24338472
26. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. PMID: 23703673
27. PLK2 inhibition is a tractable CNS pharmacological target that does not cause genotoxicity at doses and exposures that engage the target in the sensory retina. PMID: 23466428
28. Phosphorylation of Fbxw7 by Plk2 induces destabilization of the F-box protein resulting in accumulation of cyclin E and increased potential for centriole reproduction PMID: 22399798
29. have identified and validated as in vitro PLK2 and PLK3 substrates HSP90, GRP-94, beta-tubulin, calumenin, and 14-3-3 epsilon PMID: 22828320
30. Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. PMID: 22134238
31. The methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin and paclitaxel chemotherapy. PMID: 22289679
32. phosphorylation sites could play an important role in the rapid activation, expansion, and prolongation of Plk2 signaling PMID: 22100274
33. PLK2 and to a lesser extent PLK3 are superior over CK2, as catalysts of Ser-129 phosphorylation both in full length alpha-synuclein and in a peptide reproducing the C-terminal segment of the protein. PMID: 22248692
34. Acetylation of GATA-1 responsive elements in Polo-like kinase 2 plays a crucial role in Plk2 transcription and protein expression in MG-63 cells. PMID: 22138223
35. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes. PMID: 21340720
36. Results implicate Plk2 as a clinically important determinant of chemosensitivity. PMID: 21402713
37. Identification of Snk/Plk2 as a novel methylated gene in multiple myeloma. PMID: 21067440
38. NPM/B23 is a direct target of Plk2 in the regulation of centriole duplication and that phosphorylation on serine 4 can trigger this process PMID: 20352051
39. Results identify centrosomal P4.1-associated protein (CPAP), a human homologue of SAS-4, as a substrate of PLK2 whose activity oscillates during the cell cycle. PMID: 20531387
40. overexpression of PLK2 in bladder carcinomas, suggesting a possible role of PLK2 in the pathogenesis of bladder carcinomas PMID: 19506885
41. Our results point to a novel Plk2-TSC1 interaction with effects on mTOR signaling during hypoxia, and tumor growth that may enable targeting Plk2 signaling in cancer therapy. PMID: 20054236
42. there is a mitotic checkpoint wherein p53-dependent activation of Snk/Plk2 prevents mitotic catastrophe following spindle damage PMID: 12897130
43. hVPS18 may play an important role in regulation of SNK activity through its ubiquitin ligase PMID: 16203730
44. Calcipotriol affects proliferation of keratinocytes by decreasing the expression of EGR1 and PLK2 PMID: 17671831
45. is a novel target of ERRgamma, and their interaction is crucial for cancer cell proliferation PMID: 17706602
46. increased cell death observed after aphidicolin treatment and release in Plk2-deficient cells may result from both higher levels of replication stress-induced DNA damage and a dysfunctional S-phase checkpoint PMID: 17912033
47. PLK2 directly phosphorylates alpha-synuclein at Ser-129 in an in vitro biochemical assay PMID: 19004816
48. Data show that PLK2 as a kinase that phosphorylates Ser-137 of PLK1, which is sufficient to mediate this survival signal. PMID: 19706541

Show More

Hide All

HGNC: 19699

OMIM: 607023

KEGG: hsa:10769

STRING: 9606.ENSP00000274289

UniGene: Hs.398157